European myeloma network recommendations on tools for the diagnosis and monitoring of multiple myeloma: What to use and when

Caers J, Garderet L, Kortuem KM, O'Dwyer ME, Van De Donk NWCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M (2018)

Publication Type: Journal article

Publication year: 2018

Journal

Book Volume: 103

Pages Range: 1772-1784

Journal Issue: 11

DOI: 10.3324/haematol.2018.189159

Abstract

The diagnosis of multiple myeloma can be challenging, even for experienced physicians, and requires close collaboration between numerous disciplines (orthopedics, radiology, nuclear medicine, radiation therapy, hematology and oncology) before the final diagnosis of myeloma is made. The definition of multiple myeloma is based on the presence of clinical, biochemical, histopathological, and radiological markers of disease. Specific tests are needed both at presentation and during follow-up in order to reach the correct diagnosis and characterize the disease precisely. These tests can also serve prognostic purposes and are useful for follow-up of myeloma patients. Molecular analyses remain pivotal for defining high-risk myeloma and are used in updated patient strat-ifications, while minimal residual disease assessment via flow cytometry, molecular techniques and radiological approaches provides additional prognostic information on patients’ long-term outcome. This pivotal information will guide our future treatment decisions in forthcoming clinical trials. The European Myeloma Network group updated their guidelines on different diagnostic recommendations, which should be of value to enable appropriate use of the recommendations both at diagnosis and during follow-up.

Involved external institutions

Centre Hospitalier Universitaire de Liège (CHU Liège) Belgium (BE) Hôpital Saint-Antoine France (FR) Universitätsklinikum Würzburg Germany (DE) National University of Ireland (NUI), Galway Ireland (IE) Vrije Universiteit Amsterdam (VU) / University Amsterdam Netherlands (NL) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) Albert-Ludwigs-Universität Freiburg Germany (DE) Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino Italy (IT) Institut Claudius-Regaud (ICR) UNICANCER France (FR) Kantonsspital St.Gallen Switzerland (CH) National and Kapodistrian University of Athens Greece (GR) Christian-Albrechts-Universität zu Kiel Germany (DE) University of Bologna / Università di Bologna Italy (IT) Universitätsklinikum Heidelberg Germany (DE) Erasmus University Medical Center (MC) Netherlands (NL) University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven Belgium (BE) Imperial College London / The Imperial College of Science, Technology and Medicine United Kingdom (GB)

How to cite

APA:

Caers, J., Garderet, L., Kortuem, K.M., O'Dwyer, M.E., Van De Donk, N.W.C.J., Binder, M.,... Engelhardt, M. (2018). European myeloma network recommendations on tools for the diagnosis and monitoring of multiple myeloma: What to use and when. Haematologica, 103(11), 1772-1784. https://doi.org/10.3324/haematol.2018.189159

MLA:

Caers, Jo, et al. "European myeloma network recommendations on tools for the diagnosis and monitoring of multiple myeloma: What to use and when." Haematologica 103.11 (2018): 1772-1784.

BibTeX: Download